Pear Therapeutics, Inc.

Welcome to the Payer Therapeutics first quarter 2022 earnings conference call. My name is Justin, and I will be your operator today. All lines have been placed on mute to prevent background noise. This call is being recorded. A replay of the webcast will be available in the investor section of the company's website approximately two hours after completion of the call and will be archived for 30 days. I'll now turn the call over to your host, Mira Murphy, Senior Director of Corporate Communications.

Thank you, Justin. Welcome to our first quarter earnings call, and thank you for joining us today. With me today are Corian Pan, our President and CEO, Chris Guifre, our Chief Financial Officer and Chief Operating Officer, Erin Brenner, our Chief Product Development Officer, Yuri Maricich, our Chief Medical Officer, Ronan O'Brien, our General Counsel and Chief Compliance Officer, and Julia Strandberg, our Chief Commercial Officer. To start the call, I'll turn it over to Ronan for the Safe Harbor Statement.

Good afternoon. Some of the statements we make in today's call may constitute forward-looking statements. This includes statements concerning our future business, operating results, management's intentions, beliefs, and expectations about future results, events, strategies, operating plans, performance, or financial conditions, all of which are forward-looking statements within the meeting of the Private Securities Litigation Reform Act of 1995 as amended. Actual results may differ materially from those indicated by these forward-looking statements due to a variety of important factors. Additional information regarding these factors is included in our annual report on Form 10-K and quarterly report on Form 10-Q filed with the SEC. Except as required by law, PEAR assumes no obligation to update or revise these forward-looking statements, even if actual results or future expectations change materially. With that, it's my pleasure to turn the call over to Corey.